Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Xenetic Biosciences's annualized net income for the quarter that ended in Mar. 2026 was $-1.82 Mil. Xenetic Biosciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $7.17 Mil. Therefore, Xenetic Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -25.43%.
The historical rank and industry rank for Xenetic Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
XBIO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -477.04 Med: -45.51 Max: -35.28
Current: -40.07
During the past 13 years, Xenetic Biosciences's highest Return-on-Tangible-Equity was -35.28%. The lowest was -477.04%. And the median was -45.51%.
XBIO's Return-on-Tangible-Equity is ranked better than 50.75% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs XBIO: -40.07
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Xenetic Biosciences Return-on-Tangible-Equity Related Terms
Xenetic Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBIO vs ACXP, SILO, GOVX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Xenetic Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -25.43% mean?
Xenetic Biosciences (XBIO) has a Return-on-Tangible-Equity of -25.43% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #591 out of 1200 companies in the Biotechnology industry, placing it in the top 49.2%.
Is Xenetic Biosciences' Return-on-Tangible-Equity too high?
Xenetic Biosciences' current Return-on-Tangible-Equity is -25.43%. Based on the distribution chart, Xenetic Biosciences ranks #591 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xenetic Biosciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Return-on-Tangible-Equity compare to ACXP and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #591 out of 1200 companies for Return-on-Tangible-Equity. This puts Xenetic Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Return-on-Tangible-Equity is -25.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.21, compared to a current price of $2.78 — trading 33.9% below its estimated fair value. The current Return-on-Tangible-Equity is -25.43%. Xenetic Biosciences' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Return-on-Tangible-Equity is -25.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.78 is trading 33.9% below its estimated GF Value™ of $4.21.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
Return-on-Tangible-Equity: -25.43%
GF Value™: $4.21 vs. price of $2.78 (33.9% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
79GF Score
Get the complete analysis for XBIO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
